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Abstract
Background: While human cases of highly pathogenic avian influenza A (H5N1) virus infection continue to increase globally,
available clinical data on H5N1 cases are limited. We conducted a retrospective study of 26 confirmed human H5N1 cases
identified through surveillance in China from October 2005 through April 2008.
Methodology/Principal Findings: Data were collected from hospital medical records of H5N1 cases and analyzed. The
median age was 29 years (range 6–62) and 58% were female. Many H5N1 cases reported fever (92%) and cough (58%) at
illness onset, and had lower respiratory findings of tachypnea and dyspnea at admission. All cases progressed rapidly to
bilateral pneumonia. Clinical complications included acute respiratory distress syndrome (ARDS, 81%), cardiac failure (50%),
elevated aminotransaminases (43%), and renal dysfunction (17%). Fatal cases had a lower median nadir platelet count
(64.5610
9 cells/L vs 93.0610
9 cells/L, p=0.02), higher median peak lactic dehydrogenase (LDH) level (1982.5 U/L vs 1230.0
U/L, p=0.001), higher percentage of ARDS (94% [n=16] vs 56% [n=5], p=0.034) and more frequent cardiac failure (71%
[n=12] vs 11% [n=1], p=0.011) than nonfatal cases. A higher proportion of patients who received antiviral drugs survived
compared to untreated (67% [8/12] vs 7% [1/14], p=0.003).
Conclusions/Significance: The clinical course of Chinese H5N1 cases is characterized by fever and cough initially, with rapid
progression to lower respiratory disease. Decreased platelet count, elevated LDH level, ARDS and cardiac failure were
associated with fatal outcomes. Clinical management of H5N1 cases should be standardized in China to include early
antiviral treatment for suspected H5N1 cases.
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As of July 13, 2008, 385 confirmed human cases of infection
with highly pathogenic avian influenza A (H5N1) virus with 243
deaths had been reported from 15 countries since November, 2003
[1]. Although largely a panzoonotic among poultry and wild birds,
avian-to-human transmission of H5N1 virus has resulted in most
human cases [2], with rare instances of limited, non-sustained
human-to-human H5N1 virus transmission [3–5]. The continuing
propagation of highly pathogenic H5N1 viruses among poultry [6]
and migratory birds [7,8] poses a continuing and potentially
escalating threat to human populations. Preparedness for a
possible H5N1 pandemic requires not only enhanced prevention
efforts but also a heightened awareness of the clinical character-
istics of H5N1 cases among physicians.
To date, limited H5N1 clinical data are available in case reports
and limited case series from Hong Kong Special Administrative
Region (SAR), China in 1997 [9] and 2003 [10], and Vietnam
[11,12], Thailand [13–15], Indonesia [4,16], Cambodia [17],
Azerbaijan [18,19], and Turkey [20] during 2004–2006. These
observational studies described symptoms, signs, and laboratory
findings at hospital admission. Few data are available on the
clinical characteristics of cases throughout the course of H5N1
disease. Data on the natural history of H5N1 disease may allow
risk stratification and identification of prognostic factors for
outcomes of H5N1 virus infection. We describe the natural
history and report the clinical characteristics at illness onset,
hospital admission, and throughout hospitalization for 26 H5N1
cases identified by surveillance between October 2005 and April
2008.
Methods
National surveillance system and case definitions
In China, all suspected H5N1 cases are reported to the Chinese
Center for Disease Control and Prevention (China CDC, Beijing,
China) through a national surveillance system, which is based
upon reporting of hospitalized cases of pneumonia of unknown
origin, and by enhanced 1-month surveillance for cases of
influenza-like illness at all health-care facilities within a 3-km
radius after the occurrence of a suspected or confirmed H5N1
poultry outbreak with high bird mortality.
A case of pneumonia of unknown origin was defined as a
patient with all of the following criteria without specific
laboratory diagnosis: fever (temperature $38uC); radiological
evidence of pneumonia or acute respiratory distress syndrome
(ARDS); normal white blood cell count (WBC; range 4–10610
9
cells per L), leukopenia (WBC ,4610
9 cells per L), or
lymphopenia (lymphocyte count ,0.8610
9 cells per L) at
clinical presentation; and absence of clinical improvement after
treatment with broad-spectrum antibiotics. A case of influenza-
like illness was defined as a patient with fever (temperature
$38uC) and cough or sore throat, in the absence of any other
confirmed diagnosis.
A confirmed case of H5N1 was defined as a patient with
pneumonia or influenza-like illness and laboratory evidence of
H5N1 virus infection diagnosed by viral isolation or reverse
transcriptase (RT) PCR by testing respiratory specimens, or a four-
fold or greater increase in H5N1 antibody titre in paired acute and
convalescent sera.
Case-patients
All suspected H5N1 case-patients were interviewed by staff of
the local CDC, and respiratory specimens, and acute- and
convalescent-phase sera were obtained if available for laboratory
investigations following the WHO protocol [21]. Respiratory
specimens were tested by conventional [22] and real-time RT-
PCR [23] to detect H5-specific viral RNA in biosafety level (BSL)
2 facilities at the National Influenza Center (NIC) of China CDC,
and were inoculated into amniotic and/or allantoic cavities of
specific pathogen free (SPF) embryonated chicken eggs for viral
isolation [24] in enhanced BSL 3 facilities at the NIC. H5N1
antibody testing was performed on sera at the NIC by
microneutralization (MN) assay [25] in a BSL-3 laboratory, and
modified hemagglutination-inhibition (HI) assay using horse red
blood cells [26] in BSL-2 conditions.
In mainland China, 30 confirmed human H5N1 cases have
been identified to date. We included 26 laboratory-confirmed
H5N1 cases identified by surveillance in 12 provinces in China
between October 2005 and April 2008. Our analyses included
limited data from 2 case reports [27,28] and 6 urban cases
reported previously in a brief epidemiological dispatch [29]. Of the
26 cases, H5N1 virus infection was confirmed by both virus
isolation and RT-PCR in 20 (77%) cases, one (4%) case by virus
isolation only, three (11%) by RT-PCR and serology, and two
(8%) by serology only. Twenty-four cases in southern China were
infected with clade 2.3.4 H5N1 viruses, and two cases from
northern China had clade 2.2 H5N1 virus infections [2]. We
excluded four H5N1 cases, including 2 military cases with
unavailable clinical data and 2 cases in a cluster with limited
person-to-person transmission reported elsewhere [5].
Clinical investigations
A trained team from the China CDC interviewed all confirmed
H5N1 cases or their proxies, and collected clinical data through
review of hospital medical records. A standardized form was used
to collect information on demographic characteristics and clinical
data, including clinical findings, blood chemistry testing and chest
radiograph results performed during clinical management,
complications, treatments, and outcomes. Data were collected
during field investigations by China CDC staff, and was part of a
continuing public-health outbreak investigation and determined
by the Ministry of Health to be exempt from institutional review
board assessment in China.
We used the following definitions: cardiac failure was defined as
requiring use of inotropic agents; respiratory failure was defined as
the need for assisted ventilatiory support; ARDS was defined as
clinical deterioration with severe arterial hypoxaemia and diffuse
bilateral infiltrates on chest radiograph; disseminated intravenous
coagulation (DIC) was defined as elevated prothrombin time (PT)
with elevated activated partial thromboplastin time (APTT), and
decreased fibrinogen (FIB) level with thrombocytopenia; liver
function impairment was defined as aminotransferase (ALT or
AST) levels $ 26upper range of normal values; renal dysfunction
was defined as creatinine level .178mmol/L for adults or $ 26
upper limit of normal for age. High-dose corticosteroid use was
defined as $250 mg hydrocortisone or equivalent intravenous (IV)
administration daily. For children ,13 years old, high-dose
corticosteroid use was defined as $5 mg hydrocortisone or
equivalent IV/kg/day.
Statistical analysis
Medians and interquartile ranges (IQRs) were calculated for
continuous variables, and compared between fatal and nonfatal
cases using Wilcoxon rank sum test. For categorical variables,
percentages of case-patients in each category were compared using
Fisher’s exact test. Fatal cases were compared to nonfatal cases by
demographic characteristics, H5N1 virus clade, underlying
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biochemical markers at admission or during hospitalization,
clinical complications, and treatments, in the bivariate analyses
using logistic regression. All statistical tests were two-sided with a
significance level set at a=0.05. Data were analyzed with SPSS
(version 13.0, SPSS Inc, Chicago, IL, USA).
Results
Twenty-six confirmed H5N1 cases had illness onset beginning
in October, 2005 through February 2008. The median age of the
26 cases was 29 years (range 6–62) and 58% were female. Five
(19%) were children aged ,10 years old, one (4%) was 16 years
old, and 20 (77%) were adults aged .18 years.
Clinical presentation
The earliest reported symptoms and signs of 26 patients at
illness onset and noted at hospital admission are shown in Table 1.
Many patients reported fever (92%) or cough (58%) initially, but
very few reported upper respiratory symptoms such as rhinorrhea
or sore throat. All patients developed cough a median of 1 day
(IQR 1–3) from illness onset, and 85% had sputum production a
median of 3 days (IQR 1–5.3) after illness onset. Lower
respiratory tract signs and symptoms such as tachypnea and
dyspnea increased substantially from illness onset to hospital
admission. Most patients (88%) had tachypnea a median of
5 days (IQR 4–7) from illness onset and 46% reported dyspnea a
median of 6.5 days (IQR 4.5–8.5) from illness onset. Diarrhea
was reported in only one adult case at illness onset, and in two
cases at hospital admission, but developed in six patients (one
child and five adults) after hospitalization. The duration of
diarrhea in these nine (35%) cases was a median of 1 day (IQR
1–4).
All case-patients had abnormal chest radiographs at admission;
unilateral or bilateral infiltrates were observed in 10 (38%) and 16
(62%) case-patients, at a median of 6.5 days (IQR 4–7.3) and
7.5 days (IQR 6.3–9) from illness onset, respectively. The 10 case-
patients with unilateral infiltrates at admission all developed
bilateral pneumonia (Table 2). Chest radiographs showing rapid
progression from unilateral to bilateral pulmonary infiltrates and
ARDS in adult and paediatric cases are shown in Figure 1.
Radiographic findings included patchy or diffuse infiltrates or
consolidation with air bronchograms in multi-segmental or lobular
distribution.
Laboratory findings
Laboratory findings on initial testing, at admission and during
hospitalization are shown in Table 3. The prevalence of patients
with abnormal haematological findings at admission [leukopenia
(46%), lymphopenia (62%), and moderate thrombocytopenia
(50%)] increased to 92%, 89% and 73%, respectively, during
hospitalization. At admission, the median leukocyte count was
3.5610
9 cells/L (IQR 2.3–4.5) and median lymphocyte count was
0.6610
9 cells/L (IQR 0.4–1.0). These declined during hospital-
ization to a median leukocyte count of 2.3610
9 cells/L (IQR 1.5–
2.8) and median lymphocyte count of 0.3610
9 cells/L (IQR 0.3–
0.5), after a median of 8.0 days.
Abnormal percentage, peak measurement and median days
from illness onset of biochemical markers on initial testing, at
hospital admission, and during hospitalization are shown in
Table 3. Elevated ALT, AST, creatine kinase (CK), creatine
phosphokinase isoenzymes (CPK), lactic dehydrogenase (LDH),
and plasma glucose concentration, and decreased albumin levels
were observed in more than half of cases at admission, and
developed in nearly all cases during hospitalization. Elevated
creatine level was observed in 25% of cases during hospitalization.
Seventeen (77%) cases developed proteinuria at a median of
9.0 days (IQR 7.0–11) after illness onset.
Table 1. Signs and symptoms of 26 H5N1 cases at illness
onset and at hospital admission, China.
Signs and
symptoms
At illness onset,
no. (%)
At hospital admission,
no. (%)
Fever 24 (92) 18 (69)
Chills 12 (46) 12 (46)
Malaise 10 (39) 12 (46)
Myalgia 11 (42) 8 (31)
Headache 4 (15) 4 (15)
Sore throat 2 (8) 4 (15)
Rhinorrhea 3 (12) 1 (4)
Cough 15 (58) 20 (77)
Sputum production 9 (35) 15 (58)
Tachypnea
* 2 (8) 18 (69)
Dyspnea 0 6 (23)
Vomiting 2 (8) 3 (12)
Abdominal pain 1 (4) 1 (4)
Diarrhea 1 (4) 2 (8)
*Respiratory rate .24 per min.
doi:10.1371/journal.pone.0002985.t001
Table 2. Initial chest radiographic findings and progression during hospitalization of 26 H5N1 cases, China.
Initial radiographic findings No. (%)
Median days after
illness onset (IQR)
Progression during
hospitalization No. (%)
Median days after
illness onset (IQR)
Normal 0 0 No change 0 0
Unilateral infiltrates 0 0
Bilateral infiltrates 0 0
Unilateral infiltrates 10 (38) 6.5 (4–7.3) No change 0 0
Bilateral infiltrates 10 (100) 8 (6.8–9.5)
Bilateral infiltrates 16 (62) 7.5 (6.3–9) NA
* NA
* NA
*
*NA demotes not applicable
doi:10.1371/journal.pone.0002985.t002
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All cases received empiric treatment with broad-spectrum
antibiotics during hospitalization, including ceftriaxone (n=6),
moxifloxacin (n=8) and azithromycin (n=15). Corticosteroids
(median methylprednisolone dosage 1.6 [1–5] mg/kg per day IV)
were initiated at a median of 6.5 days (IQR 6.0–8.0) from illness
onset and administered to 24 (92%) cases for a median of 6 days
(IQR 3–13). Of these, 21 (88%) received high-dose corticosteroids.
Four children received late antiviral treatment. One was treated
with amantadine (100 mg per os (po) twice daily (BID) on illness
days 10–15) and ribavirin (200 mg IV/d on illness days 9–16), and
one received rimantadine (100 mg po each day (qD) on illness days
9–11); both cases survived. One child received oseltamivir
(37.5 mg po BID) on illness days 12–14, and one child was
treated with oseltamivir (40 mg po qD) on illness day 10; both
died. Eight adults received late oseltamivir treatment, including
two fatal cases – one received 75 mg po BID on illness days 8–11,
and one received both oseltamivir (75mg po BID on illness days
11–20) and rimantadine (200mg po qD on illness day 11). Six
adults treated with oseltamivir survived: one was treated with
75 mg/day on illness days 8–12, four received 75 mg BID on
illness days 4–11, illness days 8–14, illness days 10–14, and illness
days 8–12, respectively, and one was treated with 75mg BID and
amantadine (100 mg po BID) on illness days 8–12.
Two critically ill adult H5N1 cases (31-year-old male, 44-year-
old female) with ARDS were treated with convalescent plasma
obtained from one of two fully recovered H5N1 adult donor cases.
Plasma was obtained 129 days after illness onset from an adult
female case and 81 days after illness onset from an adult male case.
Both donors’ convalescent plasma tested negative for hepatitis B,
hepatitis C, and HIV, and were separated and heat-inactivated at
56uC for 10 h before transfusion. The male ARDS case received
three units (200 mL/unit) of transfused convalescent plasma
from the female donor for 2 days, beginning on illness day 13.
His H5N1 viral titre in bronchial-alveolar lavage fluid declined
substantially and was undetectable for the next 3 consecutive
days after receipt of the third convalescent plasma dose. The
female ARDS case, who had a history of bronchiectasis, received
one unit (200 mL) of transfused convalescent plasma from the
male donor once daily for 3 days, starting on illness day 13.
Further virological testing has not been done for this case. Both
cases also received oseltamivir (75 mg po BID) on illness days 10–
14 and days 8–12, respectively. Both cases recovered fully and
were discharged home.
Complications and outcomes
Twenty-three (88%) cases required ventilatory support for
respiratory failure. ARDS developed in 21 (81%) cases at a median
of 8 days (IQR 7–9) after illness onset. Liver function impairment,
renal dysfunction and cardiac failure occurred in 9 (43%), 4 (17%)
and 13 (50%) patients.
Seventeen (65%) cases died (2 children, 1 adolescent and 14
adults), including one pregnant woman at 4 months’ gestation [28]
after a median of 10 days (IQR 8–20.5). Nine (35%) nonfatal cases
were discharged at a median of 41 days (IQR 31.5–64.0) after
illness onset. Five (24%) of the 21 cases with ARDS survived,
including one pregnant woman, two adults who received
convalescent H5N1 plasma, and two other previously healthy
adults. The pregnant woman survived after developing ARDS and
experiencing a spontaneous abortion during mechanical ventila-
tion. Her pulmonary status subsequently improved and her
temperature normalised quickly; the patient was extubated and
recovered completely. All 17 fatal cases had multi-organ failure,
including respiratory failure (94%), cardiac failure (71%), renal
failure (27%) and 24% had disseminated intravenous coagulation
(Table 4).
In the bivariate analyses, demographic characteristics, year of
illness onset, clade of H5N1 virus infection, and underlying
medical conditions were similar between fatal and nonfatal cases
(Table 4). Fatal cases had significantly lower median nadir platelet
count during hospitalization (64.5610
9 cells/L vs 93.0610
9 cells/
L, p=0.02), higher median peak LDH level during hospitalization
(1982.5 U/L vs 1230.0 U/L, p=0.001), higher frequency of
ARDS (94% [n=16] vs 56% [5], p=0.034), more frequent
cardiac failure (71% [n=12] vs 11% [1], p=0.011), and shorter
median duration of corticosteroid therapy (4.0 days vs 12.0 days,
p=0.025) compared to cases that survived. A higher proportion of
cases survived that received any antiviral treatment compared to
those that did not receive antivirals (67% [8/12 patients] vs 7%
[1/14 patients], p=0.003), with a positive correlation between
antiviral therapy and disease outcome (Gamma coeffi-
cient=0.664, p=0.005).
Discussion
Our findings suggest that H5N1 disease in Chinese patients
generally begins with fever, cough, and sputum production, and
progresses rapidly to lower respiratory disease. Upper respiratory
symptoms of rhinorrhea and sore throat were less common in
China than observed in Hong Kong SAR, China [9], Thailand
[13], Turkey [21], Azerbaijan [18], and Egypt [2]. Studies suggest
that the lower respiratory tract is the major site for H5N1 viral
replication, although initial infection may occur in either the upper
or lower respiratory tract [30–33].
Figure 1. Progression of pulmonary disease in chest radio-
graphs from adult (35-year-old male, Panels A day 6 and B day
23 of illness) and pediatric (6-year-old male, Panels C day 6 and
D day 14 of illness) H5N1 cases.
doi:10.1371/journal.pone.0002985.g001
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PLoS ONE | www.plosone.org 5 August 2008 | Volume 3 | Issue 8 | e2985Table 4. Comparison of demographic and clinical features of 17 fatal and 9 nonfatal H5N1 cases, China.
Variables Fatal cases, n=17 Survivors, n=9 p-value
*
Demographic features
Male, no. (%) 7 (41) 4 (44) 1.000
Age, median (IQR) 29.0 (20.5–38.0) 26.0 (8.5–34.0) 0.403
Year
Oct 2005–Sep 2006, no. (%) 13 (76) 7 (78) 0.315
Oct 2006–Sep 2007, no. (%) 1 (6) 2 (22)
Oct 2007–Apr 2008, no. (%) 3 (18) 0 (0)
H5N1 Virus clade
Clade 2.2, no. (%) 1 (6) 1 (11) 1.000
Clade 2.3.4, no. (%) 16 (94) 8 (89)
With underlying medical conditions,
{ no. (%) 2 (12) 2 (22) 0.591
Medical care
Median time in days from illness onset to
hospitalization (IQR)
6.0 (4.5–7.5) 8.0 (7.0–9.0) 0.053
Level of hospital admission, no. (%)
County 7 (41) 1 (11) 0.276
Prefecture 6 (35) 6 (67)
Province 4 (24) 2 (22)
Haematological markers at admission
Median WBC (610
9 cells per L) (IQR) 3.8 (2.7–5.0) 3.3 (1.7–3.8) 0.196
Median LYM (610
9 cells per L) (IQR) 0.5 (0.4–1.1) 0.7 (0.4–1.1) 0.571
Median PLT (610
9 per L) (IQR) 78 (62.0–121.5) 99.0 (74.5–123.0) 0.332
Nadir measurement of haematological markers during hospitalisation
Median WBC (610
9 cells per L) (IQR) 2.0 (1.3–2.9) [16]
" 2.6 (1.7–2.8) 0.522
Median LYM (610
9 cells per L) (IQR) 0.4 (0.3–0.5) [16] 0.3 (0.3–0.5) [7] 0.922
Median PLT (610
9 per L) (IQR) 64.5 (34.5–75.0) [14] 93.0 (56.0–99.0) [7] 0.020
Biochemical markers at admission
Median ALT (U/L) (IQR) 103.0 (24.0–182.0) [15] 31.0 (18.0–50.5) 0.079
Median AST (U/L) (IQR) 168.0 (72.0–513.0) [15] 94.0 (52.5–276.5) 0.245
Median Albumin (g/L) (IQR) 29.2 (27.1–34.3) [14] 30.7 (28.7–38.6) [8] 0.339
Median CK (U/L) (IQR) 1167.5 (191.5–1420.2) [12] 597.5 (292.5–3932.8) [8] 0.792
Median CK-MB (U/L) (IQR) 66.5 (23.0–127.1) [10] 27.0 (5.0–42.0) [7] 0.161
Median LDH (U/L) (IQR) 1860.0 (796.0–2272.0) [11] 1230.0 (551.5–1549.5) 0.230
Peak measurement of biochemical markers during hospitalisation
Median ALT (U/L) (IQR) 183.0 (103.0–224.0) [13] 178.0 (78.3–458.0) [6] 1.000
Median AST (U/L) (IQR) 427.0 (165.0–734.0) [15] 159.0 (102.0–276.5) 0.084
Median Albumin (g/L) (IQR) 27.1 (24.1–29.8) [13] 30.0 (26.3–30.6) [7] 0.393
Median CK (U/L) (IQR) 1914.5 (846.8–9358.3) [12] 676.0 (537.0–4880.0)[7] 0.142
Median CK-MB (U/L) (IQR) 83.0 (72.0–282.1) [9] 74.0 (42.5–3455.0) [5] 0.606
Median LDH (U/L) (IQR) 1982.5 (1764.8–2978.3) [12] 1230.0 (1104.5–1702.0) 0.001
Complications
ARDS 16 (94) 5 (56) 0.034
Median time in days from illness onset to ARDS (IQR) 7.0 (7.0–8.8) [16] 8.0 (8.0–12.0) [5] 0.075
Respiratory failure 16 (94) 7 (78) 0.268
Liver function impairment 6/14 (43) 3/7 (43) 1.000
Renal dysfunction 4/15 (27) 0/9 (0) 0.259
Cardiac failure 12 (71) 1 (11) 0.011
DIC 4 (24) 1 (11) 0.628
Treatments
Antiviral therapy
#
Clinical Features of H5N1cases
PLoS ONE | www.plosone.org 6 August 2008 | Volume 3 | Issue 8 | e2985Diarrhea was present in only two H5N1 cases at admission, but
developed in a quarter of cases during hospitalization. Diarrhea
was a common presenting symptom among H5N1 cases in
Vietnam [11,12] and Thailand [13], but was reported infrequently
among cases in Hong Kong SAR, China [9,10], and Indonesia
[4,16]. H5N1 virus and viral RNA have been detected in feces and
intestines of human H5N1 cases [12,17,30,33]. Whether the
gastrointestinal tract is a primary site for H5N1 virus infection is
currently unknown.
Disease course in Chinese H5N1 cases was rapidly progressive;
the median time from illness onset to death in our case series is
consistent with WHO findings [2]. All H5N1 cases presented with
pulmonary infiltrates, and all cases progressed rapidly to bilateral
disease. Many cases experienced respiratory failure, ARDS, and
multi-organ failure, with hepatic dysfunction and cardiac failure.
Leukopenia and lymphopenia were also common. A recent
molecular pathology study on two cases documented that in
addition to the lungs, H5N1 virus infects the trachea and
disseminates to other organs including the brain [30]. Our
findings are consistent with other reports [11–20]. The pathogen-
esis of some clinical complications could be immunologically
mediated, as suggested by high levels of proinflammatory cytokines
and chemokines in vitro and cytokine dysregulation in fatal cases
in observational studies [10,33,34].
Five H5N1 cases were younger than 10 years old and one was
aged 16-years, in contrast to other case series [16,19–20] and the
WHO finding that the highest frequency of cases was aged 10–
19 years old [35]. The age profile of Chinese H5N1 cases may
reflect exposure differences due to traditional social and cultural
behaviours. Visiting wet poultry markets in urban areas and
exposure to sick or dead backyard poultry in rural areas before
illness onset are H5N1 risk factors in China (unpublished data,
China CDC). Paediatric cases lived in rural areas of China, and
likely had more exposures to sick/dead backyard poultry than
children in urban areas. In rural areas, young Chinese children are
much more likely to play with backyard poultry than older
children. Adults are much more likely to visit poultry markets in
urban areas of China than children and all urban adult H5N1
cases had visited a wet poultry market prior to illness onset
(unpublished data, China CDC).
In contrast to the WHO finding that cases aged 10–19 years old
had the highest case-fatality [2], mortality of H5N1 cases in China
was not associated with median age, sex or underlying medical
conditions in the bivariate analysis. Isolates from 24 cases in
southern China were characterized as H5N1 clade 2.3.4 viruses
with consistent genetic and antigenic properties from 2005
through 2008 (unpublished data, China CDC). There were no
significant differences in case-fatality ratios between years during
2005–2008 or between cases with clade 2.2 and clade 2.3.4 H5N1
virus infection. However, fatal outcomes were associated with
decreased platelet counts, increased LDH, ARDS, cardiac failure,
and lack of antiviral treatment in the bivariate analyses. In
Thailand [13] and Hong Kong SAR [9], mortality was associated
with late presentation, lower admission leukocyte, platelet, and
lymphocyte counts, bilateral pulmonary findings on chest X-ray,
and development of ARDS. Decreased leukocyte and lymphocyte
counts, and increased d-dimer levels were associated with fatal
outcomes in other studies [4,17,20,33].
Survival was significantly higher in cases that received any
antiviral treatment than in untreated cases, and 5 of 8 adult cases
that received standard oseltamivir treatment survived even though
all were treated late in their illnesses. However, it should be noted
that treatment was uncontrolled and our findings lack sequential
virological data on antiviral susceptibilities or quantitative H5N1
Variables Fatal cases, n=17 Survivors, n=9 p-value
*
No antiviral treatment 13 (76) 1 (11) P=0.003, with a
positive
correlation
#
Received any antiviral treatment 4 (24) 8 (89)
Amantadine or rimantadine only 0 (0) 3 (33)
Oseltamivir only 3 (18) 5 (56)
Combined amantadine (rimantadine) and oseltamivir 1 (6) 0 (0)
Median time in days from illness onset to initiation of
antiviral therapy (IQR)
12.0 (8.5–11.8) [4] 8.0 (8.0–9.8) [8] 0.109
Administered high-dose corticosteroids
$ 14/15 (93) 7 (78) 0.533
Median time in days from illness onset to initiation of
corticosteroids (IQR)
7.0 (6.0–10.0) [15] 8.0 (7.5–10.0) 0.174
Median days of corticosteroid therapy (IQR) 4.0 (2.0–9.0) [15] 12.0 (6.0–16.5) 0.025
Plasma therapy 0 (0) 2 (22) 0.111
*Medians were compared between fatal and survival cases with the Wilcoxon rank sum test. For categorical variables, percentages of cases in each category were
compared with Fisher’s exact test.
{NA demotes not applicable.
{Two fatal H5N1 cases had underlying medical conditions, including a 24-year-old pregnant woman [28] and a 16-year-old male with a 10-year history of minimal
change glomerulopathy. Two surviving H5N1 cases had underlying medical conditions, including a 26-year-old pregnant woman and a 44-year-old female with a ten-
year history of chronic bronchitis [unpublished data, China CDC].
#A higher proportion of cases survived that received any antiviral treatment compared to those that did not receive antivirals (67% [8/12 patients] vs 7% [1/14 patients],
p=0.003), and with a positive linear association: the Gamma coefficient equals 0.664 (p=0.005) which indicate a positive correlation between antiviral therapy and
disease outcome.
$High-dose corticosteroid use was defined as $250 mg hydrocortisone or equivalent intravenous (IV) administration daily. For children ,13 years old, high-dose
corticosteroid use was defined as $5 mg hydrocortisone or equivalent IV/kg/day.
"[]: Indicates denominators for testing of fewer cases than full group.
doi:10.1371/journal.pone.0002985.t004
Table 4. Cont.
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some H5N1 cases cannot be attributed definitively to antiviral
treatment. In contrast to clade 1 H5N1 viruses isolated in Vietnam
and clade 2.1 viruses in Indonesia [2], the clade 2.3.4 and clade
2.2 H5N1 viruses isolated from cases in China were susceptible to
both M2 inhibitors and neuraminidase inhibitors (unpublished
data, China CDC). These findings suggest roles for either class of
antiviral drugs as well as combination antiviral therapy for H5N1
cases in China [36,37].
Very few Chinese H5N1 cases received early antiviral treatment
because only one patient was admitted within two days of illness
onset, and no patients received outpatient antiviral treatment.
Antivirals were not administrated to most Chinese H5N1 cases
until they were hospitalized with pneumonia. Oseltamivir was not
available in some hospitals for treatment of some cases that died.
Therefore, education of health-care providers about the epidemi-
ological risk factors and clinical characteristics of H5N1 patients,
and wider availability of antiviral drugs could help facilitate earlier
detection and treatment of H5N1 cases in China. Although little
data on early versus late oseltamivir treatment for H5N1 patients
are available, current WHO guidance recommends initiating
oseltamivir treatment as early as possible, including consideration
of higher dosing for severe disease and longer treatment duration
because of prolonged viral replication [37].
Although antiviral therapy is the primary treatment, most
clinical management of H5N1 disease is supportive. For severely ill
Chinese H5N1 patients with ARDS or multiorgan failure,
management has focused on appropriate mechanical ventilation,
correction of hypoxemia, fluid management, and treatment of
other complications such as DIC. Corticosteroids were adminis-
tered empirically to most H5N1 cases in China. A reduction in the
proportion of cases reporting with fever from illness onset (92%) to
hospital admission (69%) may reflect an early use of corticosteroids
or non steroidal anti-inflammatory drugs. Compared to fatal cases,
nonfatal cases in China had a longer duration of corticosteroid
treatment. However, we cannot conclude that corticosteroid
therapy resulted in survival and such treatment has not been
shown to be effective in H5N1 patients [2]. Furthermore,
prolonged or high-dose corticosteroid therapy may result in
serious adverse events, including infection with opportunistic
pathogens. Recent WHO H5N1 treatment guidance recommends
against routine use of corticosteroid treatment [37].
Two cases with ARDS survived after receiving passive
immunotherapy with transfused convalescent plasma from surviv-
ing H5N1 cases. This is compelling, but since passive immuno-
therapy and other treatments were administered in an uncon-
trolled manner, no definitive conclusions can be made about the
benefit of such treatment [38]. A third Chinese H5N1 case
survived after receiving post-vaccination plasma from an H5N1
vaccine clinical trial participant and combination antiviral
treatment [5]. A meta-analysis of studies of convalescent plasma
treatment during the 1918 influenza pandemic [39], evidence
from animal experiments [40–42], and the limited experience in
three Chinese H5N1 cases suggest that passive immunotherapy
may be a viable option for the treatment of H5N1. Further
research is needed to investigate the efficacy and effectiveness of
passive immunotherapy with H5N1 convalescent plasma treat-
ment for H5N1 patients, including cases with severe complications
such as ARDS.
Our study was limited to available data for H5N1 cases
identified through surveillance during the study period. Due to the
small number of H5N1 cases, the study was too underpowered to
compare differences between fatal and nonfatal cases. National
surveillance and laboratory testing might not have identified all
H5N1 cases that occurred, especially if the cases were clinically
mild. Clinical management was uncontrolled, H5N1 viral
shedding data, immunological and pathological data were not
available, and any differences in outcomes cannot be interpreted
to be due to the use of antiviral drugs, corticosteroids, or other
uncontrolled treatments.
To improve clinical management of H5N1 patients in China,
physicians should be educated about the natural history of H5N1
disease and epidemiological risk factors, and therapy should be
standardized based upon current knowledge [37]. Early antiviral
treatment and expanded testing should be considered for
suspected H5N1 patients, with wider availability of antiviral
medications at all health care facilities. In the absence of any
definitive treatment for H5N1, preventive education to reduce risk
behaviours for H5N1 exposures (e.g. avoiding direct contact with
sick or dead poultry) must be emphasized more strongly.
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